Almirall, S.A. (ALM.MC)

8,58 +0,17 (+2,02%) Al cierre: 05:35PM CET

Almirall, S.A.

Ronda Del General Miter, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1846

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Carlos Gallardo Piqué	CEO & Chairman of the Board	50k	N/A	1972
Mr. Michael McClellan	Executive VP of Finance, CFO & Member of Management Board	N/A	N/A	1972
Mr. Eloi Crespo Cervera	Senior VP of Industrial Operations & Member of Management Board	N/A	N/A	N/A
Mr. Jordi Sabé Richer	Senior VP of Corporate Development & Member of Management Board	N/A	N/A	N/A
Mr. Esteve Conesa Panicot	Senior VP of Human Resources & Member of Management Board	N/A	N/A	N/A
Dr. Volker Koscielny	Chief Medical Officer & Member of Management Board	N/A	N/A	N/A
Mr. Pablo Alvarez	Member of Management Board, President of Almirall US & GM of Almirall US	N/A	N/A	N/A
Dr. Karl Ziegelbauer	Executive VP of R&D, CSO and Member of Management Board	N/A	N/A	N/A
Mr. Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	N/A	N/A	N/A
Ms. Isabel Gomes	General Counsel & Member of Management Board	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2015 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Almirall, S.A., a día 1 de diciembre de 2023, es 4. Las puntuaciones base son Auditoría: 4; Tablero: 4; Derechos de los accionistas: 3; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.